AE ointment	placebo	weight loss	1466	1619	participants had a significant weight loss (2.96 ± 1.6 kg, P < 0.001) that was slightly more in the case group (3.15 ± 1.5 kg vs. 2.75 ± 1.7, P = 0.375).
AE ointment	placebo	Abdominal circumference	-1	-1	AC also decreased significantly in the participants (11.3 ± 6.7 cm, P < 0.001), but the changes were more significant in the case group (13.9 vs. 6.5 cm, P = 0.004).
AE ointment	placebo	weight loss	1441	1618	At the end of the study, participants had a significant weight loss (2.96 ± 1.6 kg, P < 0.001) that was slightly more in the case group (3.15 ± 1.5 kg vs. 2.75 ± 1.7, P = 0.375)
AE ointment	placebo	Abdominal circumference	1620	1806	Abdominal circumference also decreased significantly in the participants (11.3 ± 6.7 cm, P < 0.001), but the changes were more significant in the case group (13.9 vs. 6.5 cm, P = 0.004).
AE ointment	placebo	severe drug reaction	11719	11795	There was no severe drug reaction or other complications due to AE ointment.
AE ointment	placebo	severe drug reaction	11719	11794	There was no severe drug reaction or other complications due to AE ointment
AE ointment	placebo	abdominal fat thickness	1807	2012	Similarly, abdominal fat thickness decreased significantly in the participants (2.3 ± 1.1 cm, P < 0.001), although changes were not significantly different between two groups (2.53 vs. 2.04 cm, P = 0.139).
AE ointment	placebo	abdominal fat thickness	1818	2012	abdominal fat thickness decreased significantly in the participants (2.3 ± 1.1 cm, P < 0.001), although changes were not significantly different between two groups (2.53 vs. 2.04 cm, P = 0.139).
